Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer6 Nov 2026

548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors

Ignacio Garcia-Ribas¹
Maloy Ghosh²
Sanghamitra Bhattacharjee³
Yogendra Manjunath²
Jyotsna Fuloria⁴
Ismael Rodriguez Rivera⁵
Andrae L Vandross⁶
Glenn J Hanna⁷
Ashvini Kumar Dubey³

7 affiliations

¹Imperial Cancer Research Fund/Richard Dimbleby Department of Cancer Research, St Thomas`s Hospital, London SE1 7EH
²Zumutor Biologics, Bangalore, India
³Zumutor Biologics Pvt Ltd, Bangalore, India
⁴1Zumutor Biologics Pvt Ltd, Bangalore, Karnataka, India
⁵NEXT Oncology, San Antonio, TX, USA
⁶NEXT Oncology, Austin, TX, USA
⁷Dana-Farber Cancer Institute, Boston, MA, USA

Open at source PDF DOI Cite

A neutralizing monoclonal antibody targeting species B adenoviruses largely mimics the DSG2 receptor engagement mechanism
Emilie Vassal-Stermann, Camille Berthollet, Wenli Zhang +6
Communications Biology27 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textInfectious diseaseCrossref
A Monoclonal Antibody Targeting mGluR2 Inhibits H9 Subtype Influenza A Virus Infection In Vitro.
Pengfei Wang, Chuanchuan Xing, Shengmei Jiao +2
Veterinary sciences23 Sep 2026Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.
Lisa Le Scouarnec, Vincent Bouteloup, Leslie Grasset +4
The journal of prevention of Alzheimer's disease14 Oct 2026Peer-reviewedCC BY-NC-NDFull textPhysiologyEurope PMC
535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
Yi-Long Wu, Hai-jun Guo, Chongrui Xu +5
Journal for ImmunoTherapy of Cancer6 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study
Translational Lung Cancer Research31 Aug 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{garciaribas2026phase,
  title = {{548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors}},
  author = {Ignacio Garcia-Ribas and Maloy Ghosh and Sanghamitra Bhattacharjee and Yogendra Manjunath and Jyotsna Fuloria and Ismael Rodriguez Rivera and Andrae L Vandross and Glenn J Hanna and Ashvini Kumar Dubey},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0548},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0548},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
AU  - Ignacio Garcia-Ribas
AU  - Maloy Ghosh
AU  - Sanghamitra Bhattacharjee
AU  - Yogendra Manjunath
AU  - Jyotsna Fuloria
AU  - Ismael Rodriguez Rivera
AU  - Andrae L Vandross
AU  - Glenn J Hanna
AU  - Ashvini Kumar Dubey
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0548
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0548
SN  - 2051-1426
ER  -

Related

Cite